Cullinan Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CGEM Nasdaq 2834 cullinantherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cullinan Therapeutics, Inc.

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Aug 6th, 2026 5:00 am
Cullinan Therapeutics (CGEM) Advances CLN 049 After FDA Feedback, Is The Upside Already Priced In? - Jul 29th, 2026 6:16 pm
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML - Jul 28th, 2026 5:00 am
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone - Jul 2nd, 2026 4:40 pm
Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes - Jun 23rd, 2026 3:06 am
Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing - Jun 22nd, 2026 9:40 am
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases - Jun 10th, 2026 5:30 am
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress - Jun 6th, 2026 3:15 am
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager - May 26th, 2026 5:00 am
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia - May 19th, 2026 5:00 am
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress - May 18th, 2026 3:00 pm
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - May 7th, 2026 5:00 am
Will Health Benefits Weakness Drag Elevance's Q1 Earnings? - Apr 16th, 2026 11:33 am
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data - Mar 13th, 2026 11:11 pm
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight - Mar 10th, 2026 3:31 pm
Cullinan Therapeutics: Q4 Earnings Snapshot - Mar 10th, 2026 5:23 am
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Mar 10th, 2026 5:00 am
Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference - Mar 7th, 2026 10:03 pm
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - Feb 24th, 2026 5:00 am
Cullinan Therapeutics Touts 2026 “Defining Year” as T-Cell Engager, Zipalertinib Catalysts Near - Feb 19th, 2026 6:12 pm